Skip to main content
NeuroThera Labs Inc. logo

NeuroThera Labs Inc. — Investor Relations & Filings

Ticker · NTLX ISIN · CA64136J1012 LEI · 529900GPL3C0DVADMS32 TSXV Manufacturing
Open in API
Filings indexed 88 across all filing types
Latest filing 2026-04-24 Regulatory Filings
Country CA Canada
Listing TSXV NTLX

About NeuroThera Labs Inc.

https://www.neurothera.com/

NeuroThera Labs Inc. is a clinical-stage company specializing in the development of therapeutics and advanced technologies for central nervous system (CNS) disorders and brain health. The company operates through two primary development streams. First, it is a leader in photobiomodulation (PBM) technology, developing drug-free, non-invasive devices for neurotherapy, targeting conditions such as Major Depressive Disorder (MDD), Alzheimer’s Disease, and Traumatic Brain Injury (TBI). Second, NeuroThera maintains a pharmaceutical pipeline focused on novel drug candidates, including programs based on THC and proprietary opioid/non-opioid compounds designed to enhance pain relief and treat CNS disorders. This dual approach leverages both advanced medical devices and clinical-stage drug candidates to address prevalent neurological conditions.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings Classification · 1% confidence The document is a press release announcing the company’s engagement of an investor relations service provider (bullVestor) for marketing and visibility support. It is not a financial report, earnings release, share issuance, management change, or other specific regulatory filing category. It is a general corporate announcement filed under TSXV rules. Therefore, it falls into the fallback category “Regulatory Filings” (RNS).
2026-04-24 English
News release - English.pdf
Regulatory Filings Classification · 1% confidence The document is a press release announcing Neurothera Labs’ engagement of an investor relations firm for marketing and visibility services. It does not present financial results (ER/IR), governance materials (AGM-R/CGR), share transactions (DIRS/POS), dividends (DIV), capital changes (SHA/CAP), or any meeting voting matters (DVA/PSI). It is a general regulatory announcement filed with the TSXV and serves as a miscellaneous corporate update. Therefore, it best fits under the fallback category “Regulatory Filings (RNS).”
2026-04-24 English
Report of voting results.pdf
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is a scrutineer’s report from a special shareholders’ meeting detailing vote counts for resolutions, including proxies and percentages. This aligns with “Declaration of Voting Results & Voting Rights Announcements” (code DVA) which covers official results from shareholder votes at any meeting.
2026-04-11 English
Report of voting results.pdf
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is a scrutineer’s report from a special shareholders’ meeting detailing vote counts for resolutions (Continuance Resolution and New By-Laws). It discloses formal voting results, which aligns exactly with the category “Declaration of Voting Results & Voting Rights Announcements (DVA).” It is not an AGM presentation, management update, or financial report, but a vote results announcement.
2026-04-11 English
Other securityholders documents - English.pdf
Regulatory Filings Classification · 1% confidence The document is a TSX Venture Exchange Form 5D – an Escrow Agreement under the Exchange’s Policy 5.4. It is a regulatory contract filed with the Exchange rather than a financial report, earnings release, management discussion, M&A announcement or any of the other specific categories. It does not announce results or provide a proxy statement, and is not a capital raising update or share issuance notice. It is a regulatory filing fulfilling TSX requirements, so it falls into the fallback category “Regulatory Filings” (RNS).
2026-04-03 English
News release - English.pdf
Regulatory Filings Classification · 1% confidence The document is a press release issued by Neurothera Labs Inc. announcing the granting of a U.S. patent for its cannabinoid-based antimicrobial technology. It follows the standard format of a corporate press release, including a headline, dateline, company description, and contact information. Since it does not fit into specific categories like financial reports, board changes, or dividend announcements, and is a general corporate announcement, it falls under the 'Regulatory Filings' (RNS) category as the fallback for miscellaneous corporate news.
2026-02-02 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.